CA2552002A1 - Azabenzofuran substituted thioureas as inhibitors of viral replication - Google Patents

Azabenzofuran substituted thioureas as inhibitors of viral replication Download PDF

Info

Publication number
CA2552002A1
CA2552002A1 CA002552002A CA2552002A CA2552002A1 CA 2552002 A1 CA2552002 A1 CA 2552002A1 CA 002552002 A CA002552002 A CA 002552002A CA 2552002 A CA2552002 A CA 2552002A CA 2552002 A1 CA2552002 A1 CA 2552002A1
Authority
CA
Canada
Prior art keywords
phenyl
c4alkyl
carbonyl
thiourea
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002552002A
Other languages
English (en)
French (fr)
Inventor
Andrew Thurkauf
Dawei Chen
Avinash Phadke
Shouming Li
Milind Deshpande
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Achillion Pharmaceuticals Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2552002A1 publication Critical patent/CA2552002A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CA002552002A 2004-01-06 2005-01-05 Azabenzofuran substituted thioureas as inhibitors of viral replication Abandoned CA2552002A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US53483904P 2004-01-06 2004-01-06
US60/534,839 2004-01-06
PCT/US2005/000339 WO2005067900A2 (en) 2004-01-06 2005-01-05 Azabenzofuran substituted thioureas as inhibitors of viral replication

Publications (1)

Publication Number Publication Date
CA2552002A1 true CA2552002A1 (en) 2005-07-28

Family

ID=34794326

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002552002A Abandoned CA2552002A1 (en) 2004-01-06 2005-01-05 Azabenzofuran substituted thioureas as inhibitors of viral replication

Country Status (19)

Country Link
US (1) US7439374B2 (https=)
EP (1) EP1709047B1 (https=)
JP (1) JP2007517887A (https=)
KR (1) KR20060121289A (https=)
CN (1) CN1946720A (https=)
AP (1) AP2006003659A0 (https=)
AR (1) AR047367A1 (https=)
AT (1) ATE479684T1 (https=)
AU (1) AU2005204369B2 (https=)
BR (1) BRPI0506705A (https=)
CA (1) CA2552002A1 (https=)
DE (1) DE602005023266D1 (https=)
EA (1) EA200601281A1 (https=)
IL (1) IL176486A0 (https=)
NO (1) NO20062928L (https=)
NZ (1) NZ548375A (https=)
OA (1) OA13357A (https=)
TW (1) TW200528459A (https=)
WO (1) WO2005067900A2 (https=)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200600492A (en) * 2004-05-18 2006-01-01 Achillion Pharmaceuticals Inc Substituted aryl acylthioureas and related compounds; inhibitors of viral replication
TWI329102B (en) * 2006-08-15 2010-08-21 Nat Health Research Institutes Thiourea compounds and method for inhibiting hepatitis c virus infection
BRPI0715714A2 (pt) * 2006-08-25 2014-03-11 Wyeth Corp Métodos para diminuir a frequência de emergência de uma infecção viral de hepatite c resistente ao tratamento, para atrasar a emergência de uma infecção viral de hepatite c resistente ao tratamento, para diminuir o nível de resistência de uma infecção viral de hepatite c resistente ao tratamento, para diminuir a emergência de uma infecção viral de hepatite c resistente a hcv-796, para identificar um indivíduo com uma probabilidade diminuída de responder a uma terapia viral anti-hepatite c, para monitorar, diagnosticar ou prognosticar a infecção viral de hepatite c resistente ao tratamento em um paciente, para monitorar o curso de tratamento de uma infecção viral de hepatite c em um paciente, para prognosticar o desenvolvimento de um ainfecção viral de hepatite c resistente ao tratamento em um paciente, para monitorar a infecção viral de hepatite c em um paciente e para diagnosticar o desenvolvimento de uma infecção viral de hepatite ao tratamento em um paciente
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
WO2008124300A1 (en) * 2007-04-10 2008-10-16 National Health Research Institutes Hepatitis c virus inhibitors
TW200848016A (en) * 2007-06-08 2008-12-16 Nat Health Research Institutes Thiourea compound and composition of treating hepatitis C virus infection
TWI361808B (en) * 2008-01-08 2012-04-11 Nat Health Research Institutes Imidazolidinone and imidazolidinethione derivatives
US8198284B2 (en) * 2008-04-30 2012-06-12 National Health Research Institutes Treatment of neurodegenerative disorders with thiourea compounds
US8198449B2 (en) * 2008-09-11 2012-06-12 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
SG194404A1 (en) 2008-12-23 2013-11-29 Gilead Pharmasset Llc Synthesis of purine nucleosides
KR20110098849A (ko) 2008-12-23 2011-09-01 파마셋 인코포레이티드 뉴클레오시드 유사체
PT2376088T (pt) 2008-12-23 2017-05-02 Gilead Pharmasset Llc Fosforamidatos de nucleósidos de 2-amino-purina 6-osubstituída
TWI598358B (zh) 2009-05-20 2017-09-11 基利法瑪席特有限責任公司 核苷磷醯胺
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
UY33312A (es) 2010-03-31 2011-10-31 Pharmasset Inc Fosforamidato de nucleosido de purina
PL3290428T3 (pl) 2010-03-31 2022-02-07 Gilead Pharmasset Llc Tabletka zawierająca krystaliczny (S)-2-(((S)-(((2R,3R,4R,5R)-5-(2,4-diokso-3,4-dihydropirymidyn-1(2H)-ylo)-4-fluoro-3-hydroksy-4-metylotetrahydrofuran-2-ylo)metoksy)(fenoksy)fosforylo)amino)propanian izopropylu
PT2609923T (pt) 2010-03-31 2017-08-30 Gilead Pharmasset Llc Processo para a cristalização de 2-(((s)- (perfluorofenoxi)(fenoxi)fosforil)amino)propanoato de (s)-isopropilo
AR082453A1 (es) 2010-04-21 2012-12-12 Novartis Ag Compuestos de furopiridina, composiciones farmaceuticas que los contienen y usos de los mismos
AU2011336632B2 (en) 2010-11-30 2015-09-03 Gilead Pharmasset Llc Compounds
PL2709613T5 (pl) 2011-09-16 2020-12-14 Gilead Pharmasset Llc Metody leczenia hcv
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
CN103467482B (zh) * 2012-04-10 2017-05-10 上海璎黎药业有限公司 稠合嘧啶类化合物，其制备方法，中间体，组合物和应用
PT2950786T (pt) 2013-01-31 2020-03-03 Gilead Pharmasset Llc Formulação de combinação de dois compostos antivirais
EA201690473A1 (ru) 2013-08-27 2017-03-31 ГАЙЛИД ФАРМАССЕТ ЭлЭлСи Комбинированный состав двух противовирусных соединений
CN109790143A (zh) 2016-05-10 2019-05-21 C4医药公司 用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体
CN109641874A (zh) 2016-05-10 2019-04-16 C4医药公司 用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体
EP4491236A3 (en) 2016-05-10 2025-04-02 C4 Therapeutics, Inc. Heterocyclic degronimers for target protein degradation
EP3454862B1 (en) 2016-05-10 2024-09-11 C4 Therapeutics, Inc. Spirocyclic degronimers for target protein degradation
EA202092441A1 (ru) 2016-06-07 2021-05-21 Джакобио Фармасьютикалс Ко., Лтд. Новые гетероциклические производные, применимые в качестве ингибиторов shp2
KR20240026521A (ko) 2017-03-23 2024-02-28 자코바이오 파마슈티칼스 컴퍼니 리미티드 Shp2 억제제로서 유용한 신규한 헤테로환형 유도체
EP4717317A2 (en) 2017-06-20 2026-04-01 C4 Therapeutics, Inc. N/o-linked degrons and degronimers for protein degradation
CN112839935A (zh) 2018-09-26 2021-05-25 北京加科思新药研发有限公司 可用作shp2抑制剂的新型杂环衍生物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1408198A (en) * 1971-08-23 1975-10-01 Medizinska Akad Antiviral compositions
CN1071930A (zh) * 1991-07-10 1993-05-12 伊莱利利公司 用作治疗艾滋病的人免疫缺陷病毒蛋白酶的抑制剂
GB9504460D0 (en) 1995-03-06 1995-04-26 Bayer Ag N-(3-Benzofuranyl)urea-derivatives
CA2253502A1 (en) * 1996-05-06 1997-11-13 Stephen Warren Kaldor Anti-viral compounds
US6174905B1 (en) 1996-09-30 2001-01-16 Mitsui Chemicals, Inc. Cell differentiation inducer
CN1731993A (zh) 2002-11-01 2006-02-08 维洛药品公司 苯并呋喃化合物、组合物以及治疗和预防丙型肝炎病毒感染及相关疾病的方法
CN1738797A (zh) * 2002-11-19 2006-02-22 阿基里昂药品公司 取代的芳基硫脲和相关的化合物,病毒复制的抑制剂
CA2531068A1 (en) * 2003-07-10 2005-01-27 Achillion Pharmaceuticals, Inc. Substituted arylthiourea derivatives useful as inhibitors of viral replication

Also Published As

Publication number Publication date
BRPI0506705A (pt) 2007-05-02
WO2005067900A2 (en) 2005-07-28
AU2005204369A1 (en) 2005-07-28
EP1709047B1 (en) 2010-09-01
NZ548375A (en) 2010-07-30
EA200601281A1 (ru) 2006-12-29
TW200528459A (en) 2005-09-01
EP1709047A2 (en) 2006-10-11
AP2006003659A0 (en) 2006-06-30
WO2005067900A3 (en) 2005-09-29
AU2005204369B2 (en) 2010-06-10
JP2007517887A (ja) 2007-07-05
US7439374B2 (en) 2008-10-21
OA13357A (en) 2007-04-13
AR047367A1 (es) 2006-01-18
DE602005023266D1 (de) 2010-10-14
US20050228013A1 (en) 2005-10-13
ATE479684T1 (de) 2010-09-15
KR20060121289A (ko) 2006-11-28
NO20062928L (no) 2006-08-03
IL176486A0 (en) 2006-10-05
CN1946720A (zh) 2007-04-11

Similar Documents

Publication Publication Date Title
EP1709047B1 (en) Azabenzofuran substituted thioureas as inhibitors of viral replication
EP1747196B1 (en) Substituted aryl acylthioureas and related compounds; inhibitors of viral replication
US7094807B2 (en) Substituted aryl thioureas and related compounds; inhibitors of viral replication
AU2004257277B2 (en) Substituted arylthiourea derivatives useful as inhibitors of viral replication
EP1879575A2 (en) Thiazole compounds and methods of use
US20060100225A1 (en) Heteroaryl guanidines; inhibitors of viral replication
MXPA06007729A (en) Azabenzofuran substituted thioureas as inhibitors of viral replication
AU2005326813B2 (en) Substituted aryl acylthioureas and related compounds; inhibitors of viral replication

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued